Yoskowitz Marc J 4

4 · Keenova Therapeutics plc · Filed Jun 4, 2026

AI-generated summary of this filing

Updated Jun 4, 2026

Keenova Therapeutics Director Marc Yoskowitz Receives/Forfeits RSUs

What Happened

Marc J. Yoskowitz, a director of Keenova Therapeutics plc, had restricted stock units (RSUs) settle on June 2, 2026. The filing reports 3,579 shares issued on conversion/exercise of derivative awards. Of those, 825 shares were withheld to satisfy tax withholding obligations and 2,930 RSUs were forfeited/returned to the issuer under an agreement. The filing shows no cash proceeds (prices reported as N/A or $0.00).

Key Details

Transaction date(s): June 2, 2026; Form filed June 4, 2026 (Accession 0001104659-26-070516).
Reported transactions: Conversion/exercise (3,579 shares acquired), tax withholding (825 shares withheld/disposed), forfeiture/disposition to issuer (2,930 RSUs disposed), and a related $0.00 disposition entry.
Prices/values: Reported as N/A or $0.00; no cash sale proceeds disclosed.
Shares owned after transaction: Not specified in this Form 4.
Notable footnotes: RSUs settled 1-for-1 into ordinary shares (F1); withholding amount based on a percentage and not market value because shares are not listed (F2); 2,930 RSUs forfeited in exchange for a payment from the issuer to help satisfy tax obligations related to scheduled vesting (F3); vesting schedule of these RSUs noted (F4,F5).
Filing note: This Form 4 also serves as the issuer notice required under Part V of the Companies Act 2014.

Context

These transactions reflect RSU settlement and internal adjustments (tax withholding and a contractual forfeiture), not an open-market sale or purchase. Because shares were withheld and RSUs forfeited as part of settlement/tax arrangements, the filing does not signal a cash sale by the director and no market proceeds are reported.

Form 4

Period: 2026-06-02

Director

Transactions

Exercise/Conversion
Ordinary Shares
[F1]
2026-06-02+3,579→ 4,366 total
Tax Payment
Ordinary Shares
[F2]
2026-06-02−825→ 3,541 total
Disposition to Issuer
Restricted Stock Units
[F3][F5][F4]
2026-06-02−2,930→ 8,891 total
→ Ordinary Shares (2,930 underlying)
Exercise/Conversion
Restricted Stock Units
[F1][F4]
2026-06-02−3,579→ 5,312 total
→ Ordinary Shares (3,579 underlying)

Footnotes (5)

[F1]Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU.
[F2]The number of ordinary shares withheld to satisfy tax withholding obligations arising out the vesting of RSUs is based on a percentage and did not take into account any market value as the Issuer's ordinary shares are not listed or quoted on a recognized trading market.
[F3]The Reporting Person entered into an agreement with the Issuer pursuant to which the Reporting Person forfeited the right to receive 2,930 RSUs that would otherwise have vested in exchange for a payment from the Issuer to facilitate the Reporting Person's ability to satisfy certain tax obligations related to the RSUs scheduled to vest.
[F4]The RSUs, which were granted on August 14, 2025 and October 20, 2025, vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.
[F5]The number of RSUs forfeited is based on a percentage.

Signature

/s/ Mark Tyndall, Attorney-in-Fact|2026-06-04

1 file